ReCode Therapeutics to present at Jefferies Cell and Genetic Medicine Summit

ReCode Therapeutics to present at Jefferies Cell and Genetic Medicine Summit

MENLO PARK, Calif. & DALLAS, September 22, 2022–(BUSINESS WIRE)–ReCode Therapeutics, a genetic drug company using superior delivery to power the next wave of mRNA and gene correction therapies, today announced that David Lockhart, Ph.D, President and Chief Scientific Officer of ReCode Therapeutics, will provide an overview of the company at 8:00 a.m. ET on Thursday, September 29, 2022 at the upcoming Jefferies Cell and Genetic Medicine Summit to be held in New York, NY.

About ReCode Therapeutics

ReCode Therapeutics is a genetic drug company using superior delivery to power the next wave of mRNA and gene correction therapies. ReCode’s Selective Organ Targeting (SORT) Lipid Nanoparticle (LNP) Platform is a next-generation genetic drug technology that enables precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation of ReCode’s pipeline of disease modifying mRNAs and gene correction therapies. ReCode’s main programs focus on primary ciliary dyskinesia and cystic fibrosis. ReCode leverages its SORT LNP platform and nucleic acid technologies to expand its pipeline with therapies that utilize mRNA-mediated replacement and gene correction in target organs with precise targeting of cells relevant to disease. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and on LinkedIn.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220922005033/en/

contacts

Investor contacts:
Sarah McCabe
Stern IR
sarah.mccabe@sternir.com
IR@recodetx.com

Media Contact:
Tara Cooper
The Grace Communication Group
tara@gracegroup.us
650-303-7306


#ReCode #Therapeutics #present #Jefferies #Cell #Genetic #Medicine #Summit

Leave a Comment

Your email address will not be published.